Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aurinia Pharmaceuticals reports robust Q4 earnings and navigates growth challenges

Aurinia Pharmaceuticals had a strong Q4 performance, with revenue growth and patient access milestones. Despite challenges from COVID-19 and legal disputes, the company remains financially stable and focused on driving growth through patient-centric strategies. Opportunities lie in improving patient adherence and expanding market reach.

Aurinia Pharmaceuticals reports strong Q1 performance and eyes global expansion

Aurinia Pharmaceuticals delivered robust financial performance in Q1 2023, with strong revenue growth and positive patient outcomes.
The company's strategic initiatives and globalization efforts position it well for future growth and market expansion.
Challenges such as slowing new patient starts and persistency caution require focused attention for sustained success.
Opportunities lie in enhancing patient engagement, driving revenue through new patient starts, and strengthening competitive positioning.

Aurinia Pharmaceuticals excels in Q2 earnings, eyes growth opportunities

Aurinia Pharmaceuticals delivered strong financial results in Q2 2023, driven by revenue growth, improved commercial metrics, and effective cost management.
The company's focus on patient awareness, clinical differentiation, and market access for LUPKYNIS positions it well in the competitive landscape of lupus nephritis treatment.
While facing challenges such as seasonality impact and strategic uncertainties, Aurinia remains optimistic about its financial stability, pipeline progress, and growth opportunities.

Aurinia Pharmaceuticals reports strong Q3 performance and explores growth

Aurinia Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2023, positioning itself for future growth.
While facing challenges in persistency rates and strategic decision-making, the company is leveraging upcoming guidelines and data submissions for market advantage.
Opportunities in education, regulatory approvals, and pricing strategies present avenues for sustained growth and market expansion in the lupus nephritis segment.

Aurinia Pharmaceuticals reports strong Q1 earnings and growth opportunities

Aurinia Pharmaceuticals delivered a robust performance in Q1 2024, driven by strong revenue growth and strategic cost management.
While facing challenges in managing expenses and optimizing patient outcomes, the company remains well-positioned for future profitability.
With a focus on expanding market access, enhancing treatment guidelines, and leveraging its financial strength, Aurinia is poised for continued growth and success.

Aurinia Pharmaceuticals reports robust Q2 revenue growth and strategic initiatives

Aurinia Pharmaceuticals delivered strong financial performance in Q2 2024, with notable revenue growth and operational efficiency.
While facing challenges in revenue guidance and market expectations, the company's strategic initiatives and product adoption present growth opportunities.
With a focus on product development, market expansion, and patient engagement, Aurinia is poised for continued success in the pharmaceutical industry.

Aurinia Pharmaceuticals reports robust Q3 earnings and strategic milestones

Aurinia Pharmaceuticals delivered impressive financial results in Q3 2024, showcasing growth in revenue and operational efficiency.
Despite undergoing a significant restructuring, the company remains focused on innovation, achieving milestones, and expanding its market presence.
With a strong cash position and strategic outlook, Aurinia is poised for continued success and growth in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference.

Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program.

Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program

U.S.-listed shares of Aurinia Pharmaceuticals (AUPH.O) witnessed a significant downturn, plummeting 25% to $6 in pre-market trading. The pharmaceutical company announced the conclusion of its strategic review, initiated in June 2023, but failed to attract any formal offers, a report by Reuters said.

Aurinia Pharmaceuticals shares plummet amid failed buyer hunt, 25% employee layoff plans

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2023 Earnings Call Transcript

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis after failing to attract a formal buyout offer, the company said on Thursday.

Aurinia to stop development of immunotherapies after strategic review

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company's strategic review. This includes corporate actions designed to enhance shareholder value, including an exclusive focus on driving commercial execution of the LUPKYNIS® (voclosporin) business, and a significant share repurchase prog.

Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value

Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost cuts instead, people familiar with the matter said.

Exclusive: Kidney drug developer Aurinia fails to clinch a sale, sources say

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024.

Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results.

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results

Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Submits IND Application to US Food & Drug Administration for AUR 200.

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

Alpine Immune Sciences

Journey Medical Corp

Harpoon Therapeutics Inc

Lyra Therapeutics

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?

Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan.

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

The mean of analysts' price targets for Aurinia (AUPH) points to a 59.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with LN at ACR 2023.

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis.

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Farzin Haque - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Justin Kim - Oppenheimer and Company Ed Arce - HC Wainwright Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call.

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Call Transcript

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.06 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS.

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis.

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

EDMONTON, Alberta--(BUSINESS WIRE)--Note revised call-in number for participants 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada) The updated release reads: AURINIA PHARMACEUTICALS TO RELEASE THIRD QUARTER FINANCIAL AND OPERATIONAL RESULTS ON NOVEMBER 2, 2023 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open. Auri.

News for Aurinia Pharmaceuticals Stock (AUPH)